Antiviral Evaluation of HIV-1 Specific Ribozyme Expressed in CD4+ HeLa Cells

  • John A. Zaia
  • Edouard M. Cantin
  • Pairoj S. Chang
  • Nava Sarver
  • John J. Rossi
Chapter
Part of the GWUMC Department of Biochemistry Annual Spring Symposia book series (GWUN)

Abstract

Catalytic RNA, called ribozyme, has been shown to enzymatically cleave specific sites in RNA (for reviews, see Cech and Bass, 1986, and Uhlmann and Peymen, 1990). One group of ribozymes has an active site of consensus sequences forming a “hammerhead” structure. The active center of the hammerhead ribozyme consists of 11 essential bases juxtaposed near 3 target bases (Cech, 1988). The potential versatility of this system lies in the fact that simple ribozymes can be constructed which target sites in native RNA, completing the active site in a trans configuration, and inducing cleavage (Haseloff and Gerlach, 1988). Ribozymes, which have been developed to cleave human immunodeficiency virus type 1 (HIV-1) RNA, can be transcribed in both in vitro and in vivo systems (Chang et al., 1990; Sarver et al.,1990). The purpose of this report is to review the studies evaluating the effect of ribozyme on HIV-1 RNA cleavage and on the antiviral effect in mammalian cells. Using a hammerhead motif, ribozymes were constructed which targeted a gag cleavage site, were cloned into a mammalian expression vector, and used to transform HeLa-CD4+ cells. These cells expressed HIV-1-specific ribozyme and demonstrated inhibition of HIV-1 infection.

Keywords

Dulbecco Modify Eagle Medium Hammerhead Ribozyme States Public Health Service Grant Ribozyme Expression Synthetic Ribozyme 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cech, T.R., 1988, Ribozymes and their medical implications. J. Am. Med. Assoc.260: 3030–3034.CrossRefGoogle Scholar
  2. Cech, T.R. and Bass, B., 1986, Biological catalysis by RNA, Annu. Rev. Biochem55: 599–629.PubMedCrossRefGoogle Scholar
  3. Chang, P.S., Cantin, E.M., Zaia, J.A., Ladne, P.A., Stephens, D.A., Sarver, N., and Rossi, JJ., 1990, Ribozyme-mediated site-specific cleavage of the HIV-1 genome, Clin. Biotechnol2: 23–31.Google Scholar
  4. Felgner,P., Gadek, T.R., Holm, M., Roman, R., Chan, H.W., Wenz, M., Northrop, J.P., and Ringold, G.M., 1987, Lipofectin: A highly efficient, lipid-mediated DNAtransfection procedure, Proc. Nat. Acad. Sci. USA84: 7413–7417.Google Scholar
  5. Gunning, P., Leavitt, J., Muscat, G., Ng, S-Y., Kedes, L., 1987, A human ß-actin expression vector system directs high-level accumulation of antisense transcripts, Proc. Nat. Acad. SciUSA, 84: 4831–4835.Google Scholar
  6. Hazeloff,J. and Gerlach, W.1., 1988, Simple RNA enzymes with new and highly specific endoribonuclease activitiesNature334: 585–591.CrossRefGoogle Scholar
  7. Holland, H.K., Saral, R., Rossi J.J., Donnenberg, A.D., Burns, W.H., Beschorner W.E., Farzadegan, H., Jones, R.J., Quinnan, G. V., Vogelsang, G.B., Vriesendorp, H.M., Wingard, J.R., Zaia, J.A., and Santos, G.W., 1989, Allogeneic bone marrow transplantation, zidovudine, and human immunodeficiency virus type 1 (HIV-1) infectionAnn. Intern. Med.111: 973–981.PubMedGoogle Scholar
  8. Lowary, P., Sampson, J., Milligan, J., Groebe, D., and Uhlenbeck, O.C., 1986, A better way to make RNA for physical studies, In: van Knipperberg, P.H. and Hilbers, C.N. (eds), Structure and Dynamics of RNA, p. 69,Plenum PressNew York.Google Scholar
  9. Maddon, P.J., Dalgleish, A.G., McDougal, J.S., Clapham, P.R., Weiss, R.A., and Axel, R., 1986, The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brainCell47: 333–348.PubMedCrossRefGoogle Scholar
  10. Mulligan, R.C. and Berg, P., 1981, Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase,Proc. Nat. Acad. Sci. USA, 78: 2072–2076.Google Scholar
  11. Murakawa, G.J., Zaia, J.A.,Spallone, P.A., Stephens, D.A, Kaplan, B.E., Wallace, R.B., and Rossi, J.J., 1988, Direct detection of HIV-1 RNA from AIDS and ARC patient samplesDNA, 7: 287–295.PubMedCrossRefGoogle Scholar
  12. Ratner, L., Fisher, A., Jagodzinski, L.L., Mitsuya, H., Liou, R.-S., Gallo, R.C., and Wong-Staal, F.,1987, Complete nucleotide sequence of functional clones of the AIDS virus,AIDS Res. Hum. Retroviruses, 3: 57–69.PubMedCrossRefGoogle Scholar
  13. Rossi, J.J., Cantin, E.M., Zaia, J.A., Ladne, P.A., Chen, J., Stephens, D.A., Sarver, N., and Chang, P.S., 1990, Ribozymes as therapies for AIDS.Proc. N. Y. Acad. Sciin press.Google Scholar
  14. Sarver, N., Cantin, E.M., Chang, P.S., Zaia, J.A., Ladne, P.A., Stephens, D.A., and Rossi, J.J., 1990, Ribozymes as potential anti-HIV-1 therapeutic agents, Science 247: 1222–1225.PubMedCrossRefGoogle Scholar
  15. Uhlmann, E. and Peyman, A., 1990, Antisense oligonucleotides: a new therapeutic principle,Chem. Rev.90: 5543–584.CrossRefGoogle Scholar
  16. Zaia, J.A., Rossi, J.J., Murakawa, G.J., Spallone, P.A., Stephens, D.A., Kaplan, B.E., Eritja, R., Wallace, R.B., and Cantor, E.M., 1988, Inhibition of human immunodeficiency virus by using an oligonucleoside methylphosphonate targeted to the tat-3 gene.J. Virology, 62: 3914–3917.PubMedGoogle Scholar
  17. Zaug, A.J., Been, M.D., and Cech, T.R., 1986, The Tetrahymena ribozyme acts like and RNA restriction endonuclease,Nature324: 429–433.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • John A. Zaia
    • 1
  • Edouard M. Cantin
    • 1
  • Pairoj S. Chang
    • 2
  • Nava Sarver
    • 3
  • John J. Rossi
    • 2
  1. 1.City of Hope National Medical CenterDuarteUSA
  2. 2.Beckman Research Institute of the City of HopeDuarteUSA
  3. 3.National Institute of Allergy and Infectious DiseasesBethesdaUSA

Personalised recommendations